• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

10-炔丙基-10-脱氮氨基蝶呤的合成及其抗肿瘤活性

Synthesis and antitumor activity of 10-propargyl-10-deazaaminopterin.

作者信息

DeGraw J I, Colwell W T, Piper J R, Sirotnak F M

机构信息

Bio-Organic Chemistry Laboratory, SRI International, Menlo Park, California 94025.

出版信息

J Med Chem. 1993 Jul 23;36(15):2228-31. doi: 10.1021/jm00067a020.

DOI:10.1021/jm00067a020
PMID:8340923
Abstract

Successive alkylation of dimethyl homoterephthalate with propargyl bromide and 2,4-diamino-6-(bromomethyl)pteridine followed by ester saponification at room temperature afforded 2,4-diamino-4-deoxy-10-carboxy-10-propargyl-10-deazapteroic acid. The 10-COOH was readily decarboxylated by heating in DMSO at a temperature of only 120 degrees C to yield the diamino-10-propargyl-10-deazapteroic acid intermediate. Coupling with diethyl L-glutamate and ester hydrolysis gave the title compound. The 10-propargyl analogue was about 5 times more potent than MTX as an inhibitor of growth in L1210 cells, but was only one-third as potent as an inhibitor of DHFR from L1210. The analogue was transported inward very effectively in L1210 cells showing a 10-fold advantage over MTX. At a dose of 36 mg/kg the 10-propargyl compound caused shrinkage of the E0771 solid murine mammary tumor to only 1% of untreated controls.

摘要

对苯二甲酸二甲酯与炔丙基溴和2,4-二氨基-6-(溴甲基)蝶啶进行连续烷基化反应,然后在室温下进行酯皂化反应,得到2,4-二氨基-4-脱氧-10-羧基-10-炔丙基-10-脱氮蝶酸。通过在仅120℃的温度下于二甲基亚砜中加热,10-COOH很容易脱羧,生成二氨基-10-炔丙基-10-脱氮蝶酸中间体。与L-谷氨酸二乙酯偶联并进行酯水解得到标题化合物。作为L1210细胞生长抑制剂,10-炔丙基类似物的效力约为甲氨蝶呤(MTX)的5倍,但作为L1210二氢叶酸还原酶(DHFR)抑制剂的效力仅为MTX的三分之一。该类似物在L1210细胞中非常有效地向内转运,显示出比MTX高10倍的优势。在剂量为36 mg/kg时,10-炔丙基化合物使E0771小鼠实体乳腺肿瘤缩小至未治疗对照组的仅1%。

相似文献

1
Synthesis and antitumor activity of 10-propargyl-10-deazaaminopterin.10-炔丙基-10-脱氮氨基蝶呤的合成及其抗肿瘤活性
J Med Chem. 1993 Jul 23;36(15):2228-31. doi: 10.1021/jm00067a020.
2
Synthesis and antifolate evaluation of the 10-propargyl derivatives of 5-deazafolic acid, 5-deazaaminopterin, and 5-methyl-5-deazaaminopterin.5-去氮叶酸、5-去氮氨基蝶呤和5-甲基-5-去氮氨基蝶呤的10-炔丙基衍生物的合成及抗叶酸评估
J Med Chem. 1992 Jan 24;35(2):332-7. doi: 10.1021/jm00080a019.
3
Synthesis and antifolate properties of 5,10-ethano-5,10-dideazaaminopterin.5,10-亚乙基-5,10-二去氮氨基蝶呤的合成及其抗叶酸特性
J Med Chem. 1992 Jan 24;35(2):320-4. doi: 10.1021/jm00080a017.
4
Synthesis and antifolate evaluation of 10-ethyl-5-methyl-5,10- dideazaaminopterin and an alternative synthesis of 10-ethyl-10- deazaaminopterin (edatrexate).
J Med Chem. 1992 Aug 7;35(16):3002-6. doi: 10.1021/jm00094a011.
5
Synthesis and antifolate properties of 10-alkyl-8,10-dideazaminopterins.10-烷基-8,10-二脱氮氨基蝶呤的合成及其抗叶酸特性
J Med Chem. 1984 Mar;27(3):376-80. doi: 10.1021/jm00369a024.
6
Syntheses and antifolate activity of 5-methyl-5-deaza analogues of aminopterin, methotrexate, folic acid, and N10-methylfolic acid.氨甲蝶呤、甲氨蝶呤、叶酸和N10-甲基叶酸的5-甲基-5-去氮类似物的合成及其抗叶酸活性。
J Med Chem. 1986 Jun;29(6):1080-7. doi: 10.1021/jm00156a029.
7
Analogues of methotrexate in rheumatoid arthritis. 2. Effects of 5-deazaaminopterin, 5,10-dideazaaminopterin, and analogues on type II collagen-induced arthritis in mice.
J Med Chem. 1997 Jan 31;40(3):377-84. doi: 10.1021/jm950553y.
8
Analogues of 10-deazaaminopterin and 5-alkyl-5,10-dideazaaminopterin with the 4-substituted 1-naphthoyl group in the place of 4-substituted benzoyl.
J Med Chem. 1996 Jan 19;39(2):614-8. doi: 10.1021/jm9506940.
9
Synthesis and antifolate properties of 9-alkyl-10-deazaminopterins.9-烷基-10-脱氮氨基蝶呤的合成及其抗叶酸特性
J Med Chem. 1990 Jan;33(1):212-5. doi: 10.1021/jm00163a035.
10
Methotrexate analogues. 31. Meta and ortho isomers of aminopterin, compounds with a double bond in the side chain, and a novel analogue modified at the alpha-carbon: chemical and in vitro biological studies.甲氨蝶呤类似物。31. 氨基蝶呤的间位和邻位异构体、侧链含双键的化合物以及一种在α-碳处修饰的新型类似物:化学及体外生物学研究。
J Med Chem. 1988 Apr;31(4):763-8. doi: 10.1021/jm00399a013.

引用本文的文献

1
Alkyne Derivatives of SARS-CoV-2 Main Protease Inhibitors Including Nirmatrelvir Inhibit by Reacting Covalently with the Nucleophilic Cysteine.含奈玛特韦的 SARS-CoV-2 主蛋白酶抑制剂的炔衍生物通过与亲核半胱氨酸发生共价反应来抑制。
J Med Chem. 2023 Feb 23;66(4):2663-2680. doi: 10.1021/acs.jmedchem.2c01627. Epub 2023 Feb 9.
2
Folic Acid Antimetabolites (Antifolates): A Brief Review on Synthetic Strategies and Application Opportunities.叶酸代谢拮抗剂(抗叶酸剂):合成策略和应用机会简述。
Molecules. 2022 Sep 22;27(19):6229. doi: 10.3390/molecules27196229.
3
Schedule-Dependent Synergy Between the Histone Deacetylase Inhibitor Belinostat and the Dihydrofolate Reductase Inhibitor Pralatrexate in T-and B-cell Lymphoma Cells .
组蛋白去乙酰化酶抑制剂贝利司他与二氢叶酸还原酶抑制剂普拉曲沙在T细胞和B细胞淋巴瘤细胞中的时间依赖性协同作用
Front Cell Dev Biol. 2020 Oct 9;8:577215. doi: 10.3389/fcell.2020.577215. eCollection 2020.
4
The anti-tumor activity of pralatrexate (PDX) correlates with the expression of RFC and DHFR mRNA in preclinical models of multiple myeloma.在多发性骨髓瘤的临床前模型中,普拉曲沙(PDX)的抗肿瘤活性与RFC和DHFR mRNA的表达相关。
Oncotarget. 2020 May 5;11(18):1576-1589. doi: 10.18632/oncotarget.27516.
5
Simultaneous Control of Endogenous and User-Defined Genetic Pathways Using Unique ecDHFR Pharmacological Chaperones.使用独特的ecDHFR药理伴侣同时控制内源性和用户定义的遗传途径。
Cell Chem Biol. 2020 May 21;27(5):622-634.e6. doi: 10.1016/j.chembiol.2020.03.006. Epub 2020 Apr 23.
6
Cutaneous T cell Lymphoma: an Update on Pathogenesis and Systemic Therapy.皮肤T细胞淋巴瘤:发病机制与全身治疗的最新进展
Curr Hematol Malig Rep. 2015 Dec;10(4):468-76. doi: 10.1007/s11899-015-0293-y.
7
Safety and efficacy of pralatrexate in the management of relapsed or refractory peripheral T-cell lymphoma.普拉曲沙治疗复发或难治性外周 T 细胞淋巴瘤的安全性和疗效。
Clin Med Insights Oncol. 2012;6:305-14. doi: 10.4137/CMO.S8536. Epub 2012 Aug 21.
8
The antifolates.抗叶酸类药物。
Hematol Oncol Clin North Am. 2012 Jun;26(3):629-48, ix. doi: 10.1016/j.hoc.2012.02.002.
9
Management of cutaneous T cell lymphoma: new and emerging targets and treatment options.皮肤T细胞淋巴瘤的管理:新的和正在出现的靶点及治疗选择。
Cancer Manag Res. 2012;4:75-89. doi: 10.2147/CMAR.S9660. Epub 2012 Mar 12.
10
Critical appraisal of pralatrexate in the management of difficult-to-treat peripheral T cell lymphoma.外周 T 细胞淋巴瘤治疗困难时的普拉曲沙的评价。
Ther Clin Risk Manag. 2011;7:401-8. doi: 10.2147/TCRM.S22834. Epub 2011 Oct 7.